Form 8-K - Current report:
SEC Accession No. 0001213900-24-080705
Filing Date
2024-09-20
Accepted
2024-09-20 16:45:26
Documents
14
Period of Report
2024-09-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0215265-8k_onconetix.htm   iXBRL 8-K 45301
2 AMENDED AND RESTATED FORBEARANCE AGREEMENT BETWEEN THE COMPANY AND VERU, DATED S ea021526501ex10-1_onconetix.htm EX-10.1 78113
  Complete submission text file 0001213900-24-080705.txt   317279

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE onco-20240919.xsd EX-101.SCH 3042
4 XBRL LABEL FILE onco-20240919_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE onco-20240919_pre.xml EX-101.PRE 22377
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0215265-8k_onconetix_htm.xml XML 3795
Mailing Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202
Business Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202 513-620-4101
Onconetix, Inc. (Filer) CIK: 0001782107 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41294 | Film No.: 241313908
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)